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1. Introduction
Definitions of nanotechnology vary widely. Some scientists restrict the definition to work with
molecules and devices between 1 and 100nm, while others widen these parameters to
1-1000nm. Kostoff believes that nanotechnology is best defined by the capacity to artificially
construct and manipulate structures at nanoscale, and nanoscale’s novel properties [1].
Drug loaded nanoparticles are widely utilized in the treatment of a number of diseases, such
as metabolic disorders, autoimmune diseases, inflammatory disorders, neurodegenerative
diseases and cancer. For instance, nanomedicines have been extremely useful in improving
the efficacy of small molecule drug delivery across the blood-brain barrier for the treatment
of CNS diseases [2]. In addition, nanoparticles serve as artificial oxygen carriers that can act
as a substitute for blood, saving the lives of those in dire need of transfusion [3]. Although
liposome-encapsulated formulations of Doxorubicin were being widely administered as early
as the 1990’s, nanotherapeutics is still viewed as a new and emerging field. The current chapter
will focus on the progress made using nanoparticles in cancer prevention, diagnosis and
treatment. This is certainly an area of rapid progression, with current nanotherapeutics for
cancer encompassing a vast array of nanomaterials and nanodevices [4, 5]. But some critics
believe that nanotechnology has not fulfilled its early promise and have expressed concern
that progress and investment in the laboratory has not been mirrored by comparable progress
or significant clinical success in cancer treatment [5, 6], a concern echoed in the title of Vendito
and Szoka Jr’s 2013 review: ‘Cancer nanomedicines: So many papers and so few drugs!’ [7]
However, much investment, research and development into nanotechnology diagnostics,
therapies, devices, biosensors, and microfluidics continues to provide advances in the
prevention, diagnosis and treatment of cancer [4]. Many scientists believe that nanoparticles
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are the future of diagnosis and drug delivery [8] with the potential to overcome many of the
obstacles that cancer presents.
2. Obstacles in cancer diagnosis and treatment
2.1. Late stage diagnosis
Late detection and diagnosis of cancer remains one of the fundamental causes of low survival
rates [9, 10], so developing a test that detects clinically apparent cancer before symptoms
appear is obviously an important goal [9]. The traditional biomedical imaging tools of magnetic
resonance imaging, ultrasound and positron emission tomography have several limitations in
the diagnosis of cancer, including an inadequate imaging period, a risk of renal toxicity and
an inability to detect tumor cells smaller than 1cm [6, 11]. Improvements in PET, CT and MRI,
through the use of small molecule imaging agents, such as 2-deoxy-2-(18F) fluoro-D-glucose
[FDG], iodinated small molecules and chelated gadolinium respectively, are routinely used in
the diagnosis of cancer. However, poor stability, rapid clearance and low signal intensity have
limited the use of these techniques and prompted more research into the use of nanoparticles
as a diagnostic tool [12].
2.2. Challenges in targeting, transport and delivery of treatment
Chemotherapy’s perennial problem has always been that, due to challenges presented by its
targeting, transport and delivery, a pharmacologically active concentration in tumor cells is
often only achieved at the expense of what Couvrer terms ‘massive contamination of the rest
of the body’ [13]. This toxicity can result in the use of suboptimal and/or intermittent dosing,
to allow the body to rest, or in some cases to forgo chemotherapy altogether [14].
Many traditional chemotherapeutics have poor stability and aqueous solubility. Due to this
limitation, many drugs, despite significant biological activity, are disregarded at early stages
of drug screening in the laboratory. In addition, distribution of some drugs is too general, with
only a small fraction of drugs reaching the cancer site; injected agents are often cleared by the
monocytes and macrophages of the reticuloendothelial system (RES) [15]. To be successful, a
therapeutically sufficient quantity of the drug, still in a viable state, must survive clearing and
be delivered to different regions of tumors via blood vessels, cross the vessel wall and then
finally penetrate through the interstitial space to reach the target [16], where unpredictable
blood flow and often abnormal vasculature in tumors, particularly in necrotic and semi-
necrotic regions, can make accurate delivery even more difficult [17, 18].
Other than conventional chemotherapeutic drugs, biological molecules, such as antibodies and
nucleic acids, are being widely explored for the treatment of different diseases, including
cancer. Nucleic acid drugs, such as aptamers, anti-sense DNA/RNA, and small-interfering
RNA, have shown great promise in the treatment of cancer. However, these drugs are greatly
limited by serum nucleases, opsonization and clearance by macrophages and clearance by the
renal system. Some of the nucleic acid therapeutics, such as stable nucleic-acid–lipid particle
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(SNALP), have used nanocarriers to effectively overcome the above mentioned barriers and
are being used in the treatment of cancer [19].
2.3. Chemoresistance
Chemoresistance, a major cause of cancer treatment failure, is linked to cancer stem cells (CSC).
CSCs possess unique properties, such as quiescence, mesenchymal morphology, increased
DNA repair ability, overexpression of antiapoptotic proteins, drug efflux transporters and
detoxifying enzymes [20]. These properties, together with the favorable tumor microenviron‐
ment and hypoxic stability, mean that they often escape elimination by current radio and
chemotherapies. Having survived through chemotherapy, they can give rise to metastases and
recurrent tumors which then increase in malignancy and resistance [20].
Chemoresistance can be divided into two types: intrinsic and acquired. Intrinsic chemore‐
sistance is displayed by tumor cells whose genetic and phenotypic characteristics make them
ideally suited to withstand cytotoxic agents. Acquired chemoresistance can occur after
prolonged exposure to chemotherapeutic agents, which disrupt only one of the many bio‐
chemical pathways involved in their pathogenesis. Unfortunately this approach often activates
and strengthens the alternative pathways, resulting in chemo resistant mutations in the tumor
cells and tumor relapse [18, 21, 22]. Multidrug resistance, or MDR, can also occur through a
process of cross-resistance in which cancer cells mutate and acquire resistance to multiple
structurally-related drugs and also to mechanistically different drugs, either via the over-
expression of multidrug transporters or through altered apoptosis [21], resulting in decreased
intracellular drug retention and altered tumor response [23].
2.4. The patient — Compliance and individuality
It may seem harsh to list the patient as an obstacle but, through no fault of their own, this is
often the case. Genetic variation across individuals affects a drug’s pharmacokinetics and
pharmacodynamics [24], and a breakthrough with one patient cannot always be replicated in
another. Also, each patient has different levels of tolerance to the discomfort and effects of
chemotherapy, and in many cases a pre-existing condition or illness may complicate their
cancer treatment or lead them to refuse it. Patients with comorbid illnesses and elderly patients
are those most likely to forgo or discontinue chemotherapy [14].
3. Current nanotherapeutics: Overcoming the obstacles
3.1. More accurate detection and diagnosis
Promising results have emerged from combining nanoparticle-based optical contrast agents
with existing optical imaging technologies [9]. Their ‘programmable’ surface properties and
potential for passive or active targeting make nanoparticles ideal for diagnostic imaging. The
ability of nanoshells, constructed with a silica core and gold shell, to absorb specific wave‐
lengths of light, has great potential for cancer imaging and therapeutic applications [4].
Nanotherapeutics in Cancer Prevention, Diagnosis and Treatment
http://dx.doi.org/10.5772/58419
237
3.2. Quantum dots
Semiconductor  quantum dots  are  luminescent  nanocrystals  with  great  potential  in  both
biological  and  biomedical  applications  [25].  Their  photostability,  fluorescence  intensity,
small size (2–10 nm) and tunable surfaces make them ideal for optical imaging and detecting
hundreds of cancer biomarkers in blood assays or tissue biopsies at pg/mL concentrations
[25].  The most  commonly used agents  in  the  quantum dots  are  selenides  or  sulfides  of
cadmium and zinc [12]. The wavelength of light emitted by the quantum dots depends on
their size. The light emitted is much more intense and stable than their other fluorescent
counterparts  and  hence  very  useful  in  optical  imaging  [12].  Cadmium  selenide  (CdSe),
cadmium telluride (CdTe),  indium phosphide (InP),  and indium arsenide (InAs) are the
most common quantum dot formulations used in biological applications [25]. The inorgan‐
ic core is covered by an inorganic shell, which imparts greater photostability and increas‐
es the fluorescence properties of the core [26]. The surface of the shell is coated with another
layer that enhances solubility and stability of quantum dots in the blood [26]. Often times,
the surface coating is PEG as it has low toxicity and is biodegradable. A major limitation
of quantum dots in imaging is a process called “Blinking”. This is due to fluctuation of the
quantum dots between the light emitting and non-emitting states. This limits the amount
of signal obtained at a specific time [26].
3.3. Magnetic resonance imaging
Recently, the development of nanoparticle systems to improve MRI for cancer imaging and
diagnosis has made significant progress [8]. Magnetic nanoparticles usually consist of an
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inorganic  nanoparticle  core  and  a  surface  coating  that  provides  stability  in  aqueous
dispersions. This surface coating is manipulated to facilitate targeting, real-time monitor‐
ing or both [25].  Their success,  particularly as contrast agents for MRI, is largely due to
their  enhanced proton  relaxation  and deep-tissue  imaging  capabilities,  non-invasiveness
and low toxicity [8, 25].
Supermagnetic iron oxide (SPIO) nanoparticles are now widely used as bowel contrast agents
and have been used for some time in spleen/liver imaging. SPIO nanoparticles are readily taken
up by macrophages present in the liver parenchyma (Kupffer cells) and, as liver tumors are
usually devoid of macrophages, the macrophage-specific uptake of SPIOs increases the
contrast between healthy and diseased tissue, allowing liver tumors or micro-metastases as
small as 2–3 nm to be detected [25]. SPIO nanoparticles are biodegradable as the iron molecules
released into the plasma upon degradation can bind hemoglobin. To avoid clearance of the
SPIO nanoparticles, they are often coated with PEG, which enhances the circulation time
during the imaging and treatment of prostate cancer. They are conjugated with an aptamer
that binds with high specificity and affinity to a cell surface ligand on the prostate tumor cells.
The aptamer binding to the cell surface antigen cause a localized increased accumulation of
the SPIO that enables imaging. In addition, conjugation of doxorubicin to the SPIO nanopar‐
ticles allows the targeted delivery of the chemotherapeutic drug with minimal side effects [27].
3.4. Molecular diagnostics
AuNPs (gold nanoparticles) have brought great benefits in this area, with increased sensitivity
and specificity, multiplexing capability and short turnaround times. Aptamer-conjugated NPs
can also be used for the collection and detection of multiple cancer cells [8, 28]. Gold nano‐
particles scatter light intensely. Based on the size and shape of the gold nanoparticles, the
scattering properties of the gold nanoparticles are also changed [29]. The light scattered by the
gold nanoparticles have greater photostability than the other imaging agents commonly used
[29]. Gold nanorods exhibit a phenomenon called the Surface Enhanced Raman Scattering
(SERS), which is also used in cancer diagnosis. In addition, gold nanoshells and gold nanorods
have been used to induce photothermal therapy [29]. This is an example for a “theragnostic”
agent, as the gold nanorods not only assist in diagnosis of the cancer, but also help in ablation.
3.5. Improving targeting, transport and delivery
Nanoparticles are increasingly utilized because of the multiple benefits that they offer [30].
Nanodelivery systems can make the use of chemotherapy drugs more safe and efficient by
improving delivery, cell uptake and targeting, and have been shown to improve their phar‐
macokinetic profiles and enhance their targeting at the required site [21, 31]. This success relies
on two main factors: 1] the EPR 2] The potential ability of nanodrug delivery systems to
overcome the shortcomings of many anticancer drugs [20].
1. The EPR, or enhanced permeation retention effect, exists because of two properties of
tumors. Firstly, tumor tissues have increased vasculature which allows the entry of
macromolecules and colloidal particles of diameter up to 600nm. Secondly, the lymphatic
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system is not effective in clearing the interstitial fluid from the tumor tissues [6]. Normal
tissues other than the spleen, liver and kidney are impermeable to molecules that are larger
than 2nm. Hence, nanoparticles can selectively target tumor tissues reducing toxic side
effects [6]. Together, the enhanced permeation and retention properties of the tumor over
the normal tissues cause the nanoparticle to have prolonged contact with the tumor cells.
In addition, nanocarriers also release the drug slowly, ultimately resulting in reduced
drug distribution and toxicity to normal tissues [6].
2. Once the nanoparticles reach the target tissue, cell surface receptors interact with ligand-
coated nanoparticles leading to their uptake by endocytosis. Cellular uptake of uncoated
nanoparticles is governed by their differences in size, shape and charge. It is suggested
that positively charged nanoparticles are taken up more readily due to electrostatic
attraction [32]. Interaction with specific serum proteins, results in the formation of a
corona, promoting cell entry. Recent studies indicate that non-spherical molecules, such
as rod-shaped structures, are internalized better than spherical structures [33]. Uptake of
larger nanoparticles disrupts the membrane surface, thereby inducing cell death [34].
Non-specific uptake of the nanoparticles by the lung epithelial cells and red blood cells
could cause toxic side effects.
3. Nanosized drug delivery systems can potentially overcome the shortcomings of many
anticancer drugs, such as low aqueous solubility and stability and high nonspecific
toxicity [20]. For example, paclitaxel nanoparticles stabilized with pluronic F68 are stable
for years, while the same drug in dissolved form degrades completely in less than 48 hours
[30, 35], and magnetic nanoparticles (MNPs) are increasingly used because their targeting
ability reduces systemic distribution of cytotoxic compounds in vivo and enhances uptake
at the target site, resulting in effective treatment at lower doses [8].
3.6. Nanodrug delivery systems
Nanodrug delivery can either use passive targeting mechanisms, such as the EPR effect, or
active targeting mechanisms, using ligands directed against differentially overexpressed cell
surface markers surface on tumor cells [20]. Drug encapsulation within nanoparticles can also
enhance the bioavailability of drugs administered via routes other than intravenous; both
insoluble and soluble drugs can be incorporated within nanoparticulate sols, extending their
stability as they travel through the blood, which in turn improves their overall pharmacoki‐
netic half-life [30].
By ‘pre-programming’ the degradation of nanoparticles in the body, prolonged drug release
can be achieved, eliminating the need for repetitive dosages and enabling more sustained and
consistent drug concentrations in the target area [30]. Brannon-Peppas and Blanchette have
compared the uptake of nanoparticles with more hydrophobic surfaces with those of more
hydrophilic surfaces. They concluded that a nanoparticle designed to be 100nm or less in
diameter with a hydrophilic surface will have a longer circulation time and hence a greater
ability to target the required site [17] due to reduced clearance by macrophages.
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Nanodrug delivery systems can carry one or a combination of therapeutics, including cytotoxic
agents, chemo sensitizers, small interference RNA (siRNA) and antiangiogenic agents [22].
The most commonly used platforms are described below.
Liposomes have been in use for the past several decades and are established as drug and
imaging agent carriers with proven clinical efficacy [6]. They are artificial phospholipid
vesicles 50 nm to ≥1 μm in size, either unilamellar or multilamellar (with one lipid layer or
several, arranged in onion-like layers), with one or more aqueous compartments [6, 36]. The
‘cargo’ can be held in the aqueous compartment(s) or lipid layer [37]. Liposomal nanocarriers
provide protection from degradation. Optimization of the pharmacokinetics of the encapsu‐
lated drug can improve drug accumulation in the tumor and reduce the adverse effects of bolus
administration [37].
Polymeric micelles consist of a hydrophobic core and a hydrophilic shell and are useful drug
carriers, due to their tunable size and surface functions, high monodispersity and excellent
stability. They have the ability to form hydrogels and are used for drug encapsulation or drug
conjugation [38]. Under the right conditions, pluronics, the most well-known thermosensitive
polymers, form a hydrogel at body temperature but are water soluble at 2-4°C. This allows
them to be injected as a liquid but they form a hydrogel in situ, resulting in prolonged drug
release of the encapsulated drug [36].
Dendrimers are globular macromolecular compounds consisting of an inner core, which can
be manipulated to alter its shape and size, surrounded by a series of branches with surface
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functional groups. They can carry a multiple payload of active targeting molecule, diagnostic
agent and therapeutic drug, and those with a hydrophobic core and hydrophilic surface groups
can form micelles, which can then be designed for site-specific release of their payload, via pH
and enzyme dependent mechanisms [39, 40].
Inorganic nanoparticles, such as gold nanoparticles, can be used as a cargo for drug delivery.
Gold has a number of appealing surface properties, such as light scattering, which makes them
attractive inorganic biomaterials for drug delivery when combined with nanoparticles. Due
to their ease of synthesis, biocompatibility, and affluent functionalization, many drugs can be
conjugated to the surface of gold through hydrophobic interactions. Gold–thiol conjugates are
the most common due to their accurate and predictive functionalization. Various antibiotics,
anticancer agents and oligonucleotides are also conjugated with gold nanoparticles to yield
more viable drug delivery agents. Other inorganic nanoparticles that are frequently used in
drug delivery and diagnostics include silica and iron oxide, which forms the core constituent
of many inorganic nanoparticles [41].
Porous silica based nanoparticles are highly suitable for carrying hydrophobic drugs. These
nanoparticles have a high surface-to-volume ratio and consists of large pores. The drug can be
loaded on the nanoparticles by physical adsorption and covalent linkage [42]. Nanostructured
mesoporous silicon (PSi), fabricated by electrochemical etching, have nanometer range pores
that facilitate high drug loading capabilities, irrespective of different surface chemistries.
3.7. Nanoparticles as therapeutic agents
Nanoparticles can be used as a therapeutic agent themselves. Their ability to alter the substrate
molecule, through a process called “intercrossing” upon excitation by light, is used to treat
cancer cells in the photodynamic therapy. While in the photothermal therapy, the property of
small inorganic molecules to generate heat upon excitation is taken advantage of in the
inducing apoptosis or necrosis of cells.
3.7.1. Photothermal therapy
Photothermal therapy (PTT) uses sensitizers that can absorb light in the near-infrared region
and convert it to thermal energy, causing heat in the vicinity. The sensitizer used in PTT is
usually inorganic molecules, such as gold or carbon nanoparticles. Thermal ablation therapy
has been used in the treatment of cancer for many decades, but the damage to nearby tissues
has limited the use of this technique in the treatment of cancer [43]. However, with the advent
of photodynamic therapy (PDT), targeted destruction of the tumor cell has become possible.
PEGylation and active targeting of Au nanotubes have been used in the treatment of many
cancers [44].
3.7.2. Photodynamic therapy
Photodynamic therapy (PDT) uses photosensitizers in the treatment of cancer or other
disorders. Photosensitizers are molecules that can be excited by light, which then alters
molecules in the vicinity, causing the release of singlet oxygen species (reactive oxygen
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species). ROS are capable of causing oxidative stress to the surrounding cells, causing apop‐
tosis or necrosis [12]. Photosensitizers can be excited using lasers over a wide range of visible
wavelengths. Because of the limited penetrability of visible light, photosensitizers can be used
to treat only superficial tumors, such as skin, lung, esophagus, prostate, head and neck, colon
and rectum to mention a few. Because the half-life of the reactive oxygen species is only a few
milliseconds, this therapy can be used to cause targeted cell death in regions where the
photosensitizer has accumulated. Photosensitizers can be coated with polyethylene glycol to
prevent renal clearance and to enhance the circulation time in the blood. Further antibody
conjugation to the surface can target the photosensitizer to the cancer cells that overexpress
the antigen on the surface.
3.8. Overcoming resistance
Nanovehicles carrying therapeutic drug combinations that not only target the tumor cells
selectively, but also overcome the mechanisms of drug resistance are the focus of intensive
research. This method has been proved especially effective in circumventing multidrug
resistance (MDR) in multiple cancer models [21, 36]. MDR was reversed in in vitro and in
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vivo cancer models through the co-delivery of combinations of chemo sensitizing agents and
chemotherapeutic agents [22].
3.9. Improving therapy
Nanoshells are nanoparticle beads with a thin gold outer shell and a central silica core. By
manipulating the thickness of the shell and core, the beads can be tuned to absorb and scatter
specific wavelengths of light across the visible and near-infrared (NIR) spectrum, which is very
useful in enhancing imaging properties [4].
Arguably, however, this ability to absorb light is most usefully exploited in thermal ablation
therapy. For maximum efficacy, nanoshells with a silica core diameter of ~120 nm and a 10-
nm gold shell are used in this therapy as they strongly absorb NIR light (~800 nm) and can
then create intense heat that is fatal to cells [4]. As tissue chromophores do not absorb much
energy in the NIR range, NIR light can penetrate several centimeters of human tissue without
causing harm [4].
3.10. Improving cancer prevention
The complete prevention of cancer occurrence, claims Siddiqui et al, as an unachievable goal;
cancer prevention describes ‘slowing the process of carcinogenesis’ and inhibiting its reoccur‐
rence [45]. Inefficient systemic delivery and bioavailability of chemopreventive agents has so
far limited their applicability to human medicine. However, Siddiqui et al have experimented
with encapsulating a chemopreventive agent, epigallocatechin-3-gallate (EGCG), in polylactic
acid [46] and polyethylene glycol (PEG) nanoparticles [45]. Nano-EGCG had a significantly
longer half-life and had more than a 10-fold dose advantage over nonencapsulated EGCG in
cell growth inhibition, proapoptotic, and angiogenic inhibitory effects. Curcumin derived from
turmeric, when conjugated with polymeric amphiphile, mPEG-PA or PEG, has been shown to
have more significant antiproliferative effects than the free curcumin [47, 48]. Another
nanoparticle-based formulation, called solid lipid nanoparticles (SLN), is also being used as
newer therapeutic modality to address the area of chemoprevention. The advantage is that
they act like colloidal carriers which remain as solids at room and body temperature, and so
can be efficiently used as alternatives to lipososmes and other polymeric nanoparticles [36]. A
multitude of approaches utilizing nanoparticles to combat these existing deficits in the
chemopreventive strategies will re-captivate the ‘silver bullet’ for chemoprevention in the near
future.
3.11. Improving compliance
Nanotherapeutics can be less invasive than conventional diagnosis and treatment methods.
This leads to shorter recovery times and a decreased risk of infection, and these advantages in
turn should lead to a reduction in cost and improved life expectancy and quality [49].
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4. The future: Potential risks, rewards and research
4.1. New risks: The voice of caution
With its obvious potential for breakthroughs in so many fields, it is easy to view nanotech‐
nology as an exclusively positive concept. However, it is not without risk and nanomaterials
may present greater risks than their larger counterparts, as their greater relative surface and
unique quantum effects mean they have a tendency to be more active and reactive [50]. Their
potential to cause harm is harder to predict, as it is determined using factors such as surface
area, rather than molecular structure, which is used to risk assess most other chemical hazards,
and there are no proven toxicity screening methods to evaluate them. The scarcity of infor‐
mation about how nanomaterials may impact safety, health and the environment, along with
the growing number and diversity of nanotechnologies and their associated engineered
properties, has raised serious concerns. If nanomaterials escape the laboratory or manufac‐
turing site, their degradation and interaction with substances in the environment would be
unpredictable and potentially hazardous [30, 51].
When assessing the risk to patients, it is important to bear in mind that preclinical trials of
nanodrugs may be less indicative of human risks than trials of standard medicines, and that
nanomaterials can utilize unique mechanisms and routes of exposure, potentially bypassing
the blood-brain barrier [25]. If inhaled, they may aggregate in the alveoli, where their increased
surface area places a burden on mucociliary and macrophage clearance [52].
Like any other emerging area of interest in human health, nanotechnology also has its own
demerits. A word of caution is that this research is still in its infancy to determine the unfore‐
seen side effects pertaining to nanoparticle related therapies [53]. Although our understanding
on the concepts regarding nanotherapeutics has come a long way, the exact nature of nano‐
particulate drug interactions has not been tested vigorously. Studies in animals suggest
alarming facts affecting the brain function [54-56]. With the limited current literature in
humans, it is almost impossible to judge their safety over efficacy. Hence, until a stringent risk
assessment strategy is employed, nanotherapeutics should not be viewed exclusively as a
positive concept. It is important that, if nanotechnology is to move forward safely and
sustainably, a thorough assessment of the biocompatibility and toxicity of nanoparticles is
undertaken, with potential toxicities identified and their underlying mechanisms understood
[57]. Research into the avoidance of health risks associated with nanotechnology may poten‐
tially be used to guide therapy, and vice versa [58].
5. New rewards: A bright future
5.1. Multifunction nanovehicles
Advances in MRI contrasting agents promise a next generation of agents consisting of a core
and coating conjugated to tumor-specific moieties for improved efficacy and tumor targeting
[25]. Perche and Torchillin have suggested that a possible direction for research may be the
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coupling of ligands of different natures (antibodies, proteins, peptides and chemokines,
hormone analogs) to target at least two tumor cell populations, providing more sensitive
malignant lesion detection and reducing relapses [24, 37]
Shapira looks forward to the development of ‘theragnostic’ nanovehicles that carry four major
components: a selective targeting moiety, a diagnostic imaging aid for localization of the
malignant tumor and its metastases, a cytotoxic small molecule drug(s) or innovative thera‐
peutic biological matter, and a chemosensitizing agent to neutralize drug resistance – the
advent of “quadrugnostic” nanomedicine [59].
5.2. New detection methods and diagnostic devices
Nanoparticle probes, nanocantilever, nanowire and nanotube arrays are the subject of
intensive research and are expected to solve the problem of early detection in the future [9].
Accurate localization of tumors and their metastases, via nanoparticles loaded with a diag‐
nostic aid, could in future facilitate the harnessing of other therapies, such as radiotherapy,
photodynamic therapy and surgery [59].
Heller group has described the goal of research as ‘the development of a cancer therapy
monitoring/diagnostic platform device’. This would provide real-time monitoring of patient
blood for cancer cells, cell derived nanoparticulates (such as high molecular weight DNA
fragments), and carry out cancer-related genotyping, gene expression and immunochemical
analysis [60].
5.3. New applications, new targets
Superparamagnetic iron oxide nanoparticles (crystalline magnetite structures coated with
dextran and dextran derivatives) are promising candidates for a number of applications,
including magnetic resonance imaging and drug delivery [6]. Bharali and Mousa believe that
a major potential application of these nanoparticles is the diagnosis and treatment of central
nervous system (CNS) tumors, particularly if USPIOs (ultrasmall supermagnetic iron oxide
particles) are used, as they can be utilized as intravascular contrast agents, as well as for cellular
imaging [25] One USPIO already showing great promise is Combidex, which has been
undergoing clinical trials for the detection of lymph node metastases [25].
Talekar et al predict that multifunctional superparamagnetic nanocarriers, with FR (folate
receptor) targeting and pH mediated drug release, can be developed to achieve a decrease in
tumor volume, as well as improved MRI sensitivity and decreased adverse effects [6]. Metal
coordination complexes also offer a diversity of formulations and the prospect of mechanisms
that differ from those of organic drugs, including ligand substitution and metal-and ligand-
centered redox properties [31].
Therapeutic and imaging nanoparticles have normally used passive targeting to date, but
active targeting needs to be used and further developed if drugs are to be delivered to specific
classes of cells and specific intracellular sites in cancer cells [31].
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5.4. Reducing the side effects
Nanoparticle encapsulation has already been shown to reduce unwanted accumulation of
platinum in the kidneys from the platinum [59] prodrug mitaplatin, and reports show that
metallodrugs loaded in nanoparticles cause less damage than the drugs on their own. So
these formulations are predicted to be in line for further research and exploitation in the
near future [31].
6. Bench to bedside: Translational perspectives
Nanotechnology has raised as many questions as it has answered, and spawned new and
unpredicted fields [61]. With its vast array of potential applications in so many fields of science
and industry, it is a prime candidate for multidisciplinary collaboration, and the urgent need
to see laboratory breakthroughs translated to clinical successes is increasingly recognized.
Biochemists are increasingly working with scientists from fields not usually associated with
medicine, and the NIH’s Nanomedicine Development Centers are staffed by multidisciplinary
research teams, including biologists, physicians, mathematicians, engineers, and computer
scientists, whose first task has been to research the chemical and physical properties of
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nanoscale biological structures [58]. Baseline work of this sort is vital if clinicians are to have
the knowledge to develop new therapies.
Murday et al claim that translational research has been ‘a powerful process that drives the
clinical research engine’, but feel that a stronger research infrastructure is needed in future to
‘strengthen and accelerate this critical part of the clinical research enterprise [58]. Kawasaki
and Player agree that scientists from all fields must make a strenuous effort to integrate and
coordinate the research in an approach that might now be described as ‘systems biology’. They
hold up the 2004 article ‘Electronic structure and bonding of Au on a SiO2 cluster: a nanobullet
for tumors’ [46], produced by physicists, as a prime example of how research in other fields
can advance nanomedicine [46, 62].
7. Conclusions
Nanotherapeutics have already yielded significant breakthroughs in the detection, diagnosis
and treatment of cancer, and appear to have the potential to yield many more, with extensive
and focused routes of research planned for the future and the possibility of nanotechnology-
based cancer prevention. But it is clear that nanotechnology must be thoroughly understood
and its risks assessed if it is to be developed safely, and that the expertise of researchers in
many fields needs to be brought together to move new discoveries out of the laboratory and
into the clinical environment where patients can reap the benefits.
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